Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMC-A12 +/- Cetuximab in Recurrent/Metastatic Head and Neck Cancer
NCT00617734Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2008
- Primary completion
- Feb 2012
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cixutumumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Eli Lilly and Company. Started Mar 2008; status: completed.
02
Drugs
cixutumumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00617734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00617734.